SciClone Pharmaceuticals

SciClone Pharmaceuticals, Inc. (SciClone ) is a global specialty pharmaceutical company with a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. SciClone’s proprietary lead product, ZADAXIN (thymalfasin), may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as an immune system enhancer, according to the local regulatory approvals. The Company has successfully in-licensed and commercialized products with the potential to become future market leaders and to drive the Company's long-term growth, including DC Bead, a novel treatment for liver cancer, approved in China, and several other products in late-stage development in China. 

Company Growth (employees)
Type
Public
HQ
Foster City, US
Founded
1989
Size (employees)
570 (est)
SciClone Pharmaceuticals was founded in 1989 and is headquartered in Foster City, US

SciClone Pharmaceuticals Office Locations

SciClone Pharmaceuticals has an office in Foster City
Foster City, US (HQ)
900 950 Tower Ln

SciClone Pharmaceuticals Data and Metrics

SciClone Pharmaceuticals Financial Metrics

SciClone Pharmaceuticals's revenue was reported to be $42.9 m in Q1, 2017
USD

Revenue (Q1, 2017)

42.9 m

Gross profit (Q1, 2017)

36.7 m

Gross profit margin (Q1, 2017), %

86%

Net income (Q1, 2017)

14.6 m

EBIT (Q1, 2017)

14.2 m

Market capitalization (18-Aug-2017)

591.1 m

Cash (31-Mar-2017)

141.3 m
SciClone Pharmaceuticals's current market capitalization is $591.1 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

127.1 m134.8 m157.3 m160.1 m

Revenue growth, %

6%17%2%

Cost of goods sold

22.3 m22.9 m

Gross profit

134.9 m137.2 m

Gross profit Margin, %

86%86%

Operating expense total

127.3 m126.9 m

EBIT

10.4 m26 m29.9 m33.2 m

EBIT margin, %

8%19%19%21%

Net Income

11 m25.2 m29.5 m30.7 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

32.5 m34.3 m33.6 m37.9 m42.9 m36.5 m39 m40.5 m42.9 m

Cost of goods sold

5 m6 m4.6 m5.7 m6.9 m5.8 m5.7 m5.6 m6.2 m

Gross profit

27.5 m28.3 m29 m32.3 m36 m30.7 m33.3 m35 m36.7 m

Gross profit Margin, %

85%82%86%85%84%84%85%86%86%

Sales and marketing expense

11.2 m13.9 m11.1 m13 m15.1 m12.4 m14.4 m13.3 m12.8 m

R&D expense

804 k653 k1.1 m6.6 m1 m1.5 m4.8 m3.3 m2.5 m

General and administrative expense

5.8 m5.6 m7.3 m6.8 m7.3 m7.4 m8.1 m7.9 m7.2 m

Operating expense total

17.9 m20.2 m19.5 m26.3 m23.4 m21.3 m27.3 m24.5 m22.5 m

EBIT

9.6 m8.1 m9.5 m(4.9 m)12.6 m9.4 m6 m10.5 m14.2 m

EBIT margin, %

30%24%28%(13%)29%26%15%26%33%

Net Income

9.6 m7.9 m9 m(4 m)12 m7.9 m6.3 m10.1 m14.6 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

85.8 m86.2 m101.4 m134.4 m

Accounts Receivable

40.3 m

Inventories

15.2 m10.7 m11 m16.6 m

Current Assets

143.4 m140.2 m168.5 m195.7 m

PP&E

843 k1.8 m2.7 m2 m

Goodwill

35.4 m34.5 m33 m30.8 m

Total Assets

180.2 m181.8 m216.6 m241.9 m

Accounts Payable

7.2 m5.3 m4.5 m3.6 m

Current Liabilities

33.6 m26.4 m36.8 m26.4 m

Additional Paid-in Capital

278.3 m287.1 m296.1 m304.6 m

Retained Earnings

(136 m)(135.1 m)(118.5 m)(87.8 m)

Total Equity

146.6 m155.3 m179.7 m215.4 m

Financial Leverage

1.2 x1.2 x1.2 x1.1 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

87 m96.8 m96 m93 m99.2 m114.7 m117.6 m130.1 m141.3 m

Accounts Receivable

32.4 m

Inventories

16.3 m14.2 m8.9 m12 m12.1 m12.2 m11.3 m13.8 m15.3 m

Current Assets

141.3 m146.7 m140.1 m146.4 m153.8 m162.2 m167.7 m184.2 m207.1 m

PP&E

1.2 m1.6 m2.5 m2.5 m2.2 m2.4 m2.1 m1.8 m1.8 m

Goodwill

34.5 m34.9 m34.5 m34.5 m33.7 m33.2 m32.3 m32.1 m31.1 m

Total Assets

177.5 m186.2 m182.3 m195.9 m202.2 m210.4 m214.5 m233.4 m253.5 m

Accounts Payable

6.6 m6.4 m2.4 m5.4 m3.8 m3.3 m2.6 m4.7 m2 m

Current Liabilities

23.3 m26 m18.8 m35.2 m36.2 m20.8 m21.4 m24.6 m20 m

Additional Paid-in Capital

281.4 m285.2 m289 m292.7 m294.3 m297.8 m295.8 m301.4 m307.8 m

Retained Earnings

(130.8 m)(128.8 m)(128.9 m)(135.5 m)(131 m)(110.6 m)(104.3 m)(94.2 m)(73.3 m)

Total Equity

154.1 m160.2 m163.4 m160.6 m166 m189.5 m193 m208.7 m233.4 m

Financial Leverage

1.2 x1.2 x1.1 x1.2 x1.2 x1.1 x1.1 x1.1 x1.1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

11 m25.2 m29.5 m30.7 m

Depreciation and Amortization

860 k852 k931 k985 k

Accounts Receivable

(4.2 m)(3.3 m)306 k(2.4 m)

Inventories

(4.7 m)5.9 m1.4 m(3 m)

Accounts Payable

(652 k)(5.5 m)(2.3 m)(3.1 m)

Cash From Operating Activities

9.5 m27.6 m32.5 m34.5 m

Purchases of PP&E

(324 k)(1.5 m)(1.8 m)(648 k)

Cash From Investing Activities

55 k(6.2 m)(9 m)(3.4 m)

Cash From Financing Activities

(8.4 m)(20.8 m)(8.4 m)1.9 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

9.6 m7.9 m9 m(4 m)12 m7.9 m6.3 m10.1 m14.6 m

Accounts Receivable

32.4 m

Inventories

16.3 m14.2 m8.9 m12 m12.1 m12.2 m11.3 m13.8 m15.3 m

Accounts Payable

6.6 m6.4 m2.4 m5.4 m3.8 m3.3 m2.6 m4.7 m2 m
USDY, 2017

Revenue/Employee

75.2 k

Financial Leverage

1.1 x

SciClone Pharmaceuticals Market Value History

Traffic Overview of SciClone Pharmaceuticals

SciClone Pharmaceuticals Company Life and Culture

You may also be interested in